Clinical Research Professionals Lecture Series

• New Lecture Series geared to bring innovative and new topics to Clinical Research Professionals at Johns Hopkins
• [https://ictr.johnshopkins.edu/events/clinical-research-professionals-lecture-series/](https://ictr.johnshopkins.edu/events/clinical-research-professionals-lecture-series/)
• Topics are based on questions received from Clinical Research Professionals throughout Hopkins
• Welcome topic suggestions: sswords1@jhmi.edu
• Welcome speakers!
Agenda

• No Surprises Act
  —Karen Roz & Liza Rodríguez

• New IND/IDE Policy
  —Mark Sulkowski

• Questions and Discussion
No Surprises Act and Maryland Outpatient Facility Fee Notice

Karen Roz, MS  
Director  
Clinical Research Support Services

Liza Rodríguez, MS  
Sr. Associate Director  
Clinical Research Billing Compliance
No Surprises Act

• Applies to:
  — Emergency services
  — Non-emergency services from out-of-network providers in an on-network facility
  — Services from out-of-network air ambulance service providers

• Bans surprise billing / balance billing

• Facility and providers must provide an easy-to-understand notice explaining who to contact and all applicable protections

• Process to dispute bills
No Surprises Act

• What about self-pay patients?
  — Patient should receive a good faith estimate
  — This can be confusing to research participants
Maryland Outpatient Facility Fee Notice

• Maryland’s Facility Right-to-Know Act
  — Effective on July 1st, 2021

• Notice to all outpatient patients- including research participants:
  — Patient has an upcoming visit on a facility outpatient site
  — Patient will receive a facility and a professional fee bill
  — There is financial assistance available if the patient cannot pay
  — The facility fee might change depending on the location
Maryland Outpatient Facility Fee Notice

• The notice is/can be verbal, written and in MyChart

• The facility fee notice (letter) will change slightly, depending if it the scheduled visit is linked to research or not
Whenever you receive outpatient care at Johns Hopkins regardless of whether this is for research or clinical care, you will receive a notification from Johns Hopkins prior to your visit that will be an estimate of the total cost of care for that visit. This is required by The Maryland’s Facility Right-to-Know Act, better known as the Maryland Outpatient Facility Fee Notice. The cost estimate will cover the cost of all care that will be provided and does not exclude costs that may be covered by the research study. You will not be billed for research activities that are covered as detailed in the Insurance and Research Participant Financial Responsibility Information Sheet that you were provided with when you signed consent for the research study.
**This is not a bill**

Whenever you receive outpatient care at Johns Hopkins regardless of whether this is for research or clinical care, you will receive a notification from Johns Hopkins prior to your visit that will be an estimate of the total cost of care for that visit. This is required by The Maryland’s Facility Right-to-Know Act, better known as the Maryland Outpatient Facility Fee Notice. The cost estimate will cover the cost of all care that will be provided and does not exclude costs what may be covered by the research study. You will not be billed for research activities that are covered as detailed in the Insurance and Research Participant Financial Responsibility Information Sheet that you were provided with when you signed consent for the research study.

You can call 844-986-1584 for information about estimates or visit the Billing and Insurance webpage at [https://www.hopkinsmedicine.org/patient_care/patients-visitors/paying-insurance/](https://www.hopkinsmedicine.org/patient_care/patients-visitors/paying-insurance/) for details about insurance, estimates and more. Should you have additional questions, please contact the research team.

### Important Information about Your Estimate

**Estimated Charges**

<table>
<thead>
<tr>
<th>Facility/Hospital</th>
<th>Service</th>
<th>Description</th>
<th>Estimated Charge</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td></td>
<td><strong>$14.40</strong></td>
</tr>
</tbody>
</table>

**This charge is related to a research study.**

You are enrolled in a research study. These charges are related to your study. Please refer to the Research Participant Financial Responsibility Information Sheet. This will contain information about costs that will be covered for the study or that may be charged to you or your insurance. Please contact the research team if you have additional questions.
The Maryland’s Facility Right-to-Know Act, better known as the Maryland Outpatient Facility Fee Notice, became effective on July 1, 2021, and it requires Johns Hopkins Medical Institutions located in Maryland to provide a written notice with an estimate of outpatient hospital fees (hereafter “facility fee”) for a scheduled service or procedure at the location selected.

Below you will find a few frequently asked questions about the process used by Johns Hopkins Medical Institutions (JHM) to comply with the required notice that will help you address inquiries from your research participants:

What is different for the research participant when scheduling an outpatient hospital-based appointment? Research participants will be provided information, orally or through MyChart, at the time an appointment is scheduled. This includes statements about the location (i.e., that an outpatient hospital setting was selected), that the research participant will receive a facility and professional fee bill, that there is financial assistance available if the research participant cannot pay, and that the facility fee might change if the service or procedure is performed in a location where facility fees may not be charged. Additionally, the research participant will receive a written notice in MyChart or by regular mail with an estimate of the charges. The estimate is based on typical or average facility fees for the location selected.

Is the facility fee notice a bill? No. It is an estimate of hospital charges based on the service/procedure scheduled and the Maryland outpatient hospital-based facility selected.

Does the research participant have to make a payment based on the notice before the scheduled appointment? The notice letter is an estimate and not a bill.

Will research participants receive these notices for standard of care and research services or procedures? Research participants might receive letters related to the standard of care portion of the clinical trial that will be billed and processed as before. Note that costs specifically related to research may be included on the estimate and will not be billed to the research participant. These charges are reviewed and routed to the study prior to the issuance of a bill. If the study pays for all costs related to research, you can advise the research participant to ignore the letter for scheduled visits linked exclusively to the clinical trial.

Why is the facility fee being sent to the research participant instead of the participant’s insurance being billed? The letter is automatically generated by the JHM system based on the information available at the time the appointment was scheduled. If there is no insurance attached to the appointment or if the research participant is scheduled as well pay, the full amount of the expected hospital charges will appear in the notice. The research participant will be able to update their insurance when they arrive and register for their scheduled appointment.

What can I do to help research participants understand the actual likely cost of their participation on the study? Review the Financial Responsibility Information Sheet at the time of the informed consent and any time that research participants have questions about research-related charges. This form outlines the services and procedures that will be covered by the study. Provide “The Maryland Outpatient Facility Fee Notice and Research Participant Information FAQs” document to the research participants. Please note that the outpatient facility notice letter directs questions to the research staff and advises the research participant to use the Financial Responsibility Information Sheet.

What should I do if a research participant on my study has questions I cannot answer? The research participant should call the cost estimates assistance line at 844-986-1884 for more information.
New Epic Research Icon!

- Epic August 4\textsuperscript{th} upgrade (vMay2022)
Contacts

Karen Roz, MS
Director
Clinical Research Support Services
rozka@jhmi.edu
CRSS@jhmi.edu

Elizabeth (Liza) Rodríguez, MS, RHIA
Sr. Associate Director
Clinical Research Billing Compliance
erodri13@jhmi.edu
CLINIRESBILLING@exchange.johnshopkins.edu
Johns Hopkins University
IND-IDE Policy, Effective June 1, 2022

Mark Sulkowski, MD
Senior Associate Dean for Clinical Trials
and Capital Research
JHU Policy for investigator-sponsored IND/IDE
Faculty who serve as IND/IDE holders commit to additional regulatory responsibilities [e.g. safety reporting to the FDA]

JHU is ultimately responsible

Until recently, no institutional policies outlining who may serve in the role of IND/IDE sponsor nor any institutional checks

New COI policy imposes restrictions on faculty’s ability to serve in this role but there are no early system checks for conflicts

Starting in 2019, peer comparison was initiated – most peers offer some centralized IND/IDE registration, qualification, and support
JHU Investigator-held IND/IDEs

• JHU SOM IRB: investigator-held “full” IND/IDEs (2021)
  — 251 protocols with investigator-held INDs:
    ▪ Expanded access/compassionate use – 19 [Not included in the JHU policy]
    ▪ 232 protocols under 165 INDs held by 95 JHU investigators
  — 20 protocols with investigator-held IDEs:
    ▪ Expanded access/compassionate use – 3 [Not included in the JHU policy]
    ▪ 17 protocols under 17 IDEs held by 15 JHU investigators

• Largest # of protocols associated with investigator-held INDs/IDEs are in SKCCC (~36%) and Radiology (~26%)

• Minimal IND/IDEs held outside SOM
Insufficient IND/IDE support structure: Creates inefficiency and non-compliance risk

• Robust infrastructure needed to adhere to the FDA requirements
• Inefficiency due to limited guidance/directions for investigators
• Learning of requirements/restrictions at the time of IRB/COI review is “too late”
• Anticipate a significant increase in IDEs to implement Machine Learning/AI algorithms and INDs for first-in-human trials.
• Investigators encounter barriers when trying to develop Hopkins-generated IP
  —Central process with the potential to improve throughput
Johns Hopkins University IND/IDE Policy

• Approved January 2022: Investigator-held INDs/IDEs

• Effective June 1, 2022
  — Investigators seeking to file a new IND/IDE on/after this date must comply with the policy
  — *Not single patient/compassionate use requests*
  — All JHU investigators - not just JHM
  — Office of Clinical Trials is responsible for operationalizing this policy
Core Components: Faculty Qualifications

• Full-time member of JHU faculty and be a JHHS credentialed, U.S. licensed medical provider (physician or dentist), unless the exception set forth in section II.B for certain Ph.D. faculty applies.
  — Designated medical monitor in these circumstances

• Knowledge of FDA IND/IDE regulations and Good Clinical Practice (GCP)
  — Must at a minimum complete GCP training

• Demonstrate the availability of adequate resources to meet the obligations of a Sponsor-Investigator inclusive of:
  — Research staff experienced with FDA regulated research
  — Adequate time and resources
Core Components: Faculty Qualifications

• No outstanding, unresolved compliance concerns

• No individual Financial Conflict of Interest (FCOI) with respect to either the funder of the study, or the drug, biologic, or device under investigation, and not directly report to someone who has such an FCOI.
  — Exceptions considered for minimal risk research

• Additional restrictions may be imposed where there are institutional conflicts of interest
Core Components: Key Requirements

• Creates a mandatory registration process prior to filing new INDs/IDEs
• Correspondence to the FDA is copied to the OCT
• Investigational drugs managed by IDS or an alternative approved process
• Investigational device storage approval
• Additional requirements for the manufacture of drugs or devices, where applicable
Core Components: Multi-site studies conducted under a JHU investigator-held IND/IDE

• Plan for monitoring all sites where the research will be conducted
• Monitoring carried out by an appropriately qualified CRO or monitoring program pre-approved by the OCT
• Reports from the monitoring copied to the OCT
• Outline a plan detailing which IRB will serve as the IRB of record
Core Components: Procedural Requirements

• Registration requires a letter of support from the Chair/Director of the Department/Institute to which the proposed sponsor-investigator reports

• OCT will issue a **Notice of IND/IDE Suitability** if the individual is approved to serve as sponsor-investigator
  — Faculty experts may be consulted if needed

• If there are concerns the faculty member and Department/Division Chair/Director will be notified and given an opportunity to address the concerns

• IRB needs documentation of this notice before approval
Questions?

Contact Information:

Stephanie Swords: sswords1@jhmi.edu
Karen Roz: rozka@jhmi.edu
Liza Rodríguez: erodri13@jhmi.edu
Mark Sułkowski: msulkowski@jhmi.edu